Daewoong Pharmaceutical Co., Ltd (069620.KS) Stock

069620.KS logo

Daewoong Pharmaceutical Co., Ltd

069620.KSSouth Korea
Healthcare

Company profile

Daewoong Pharmaceutical reported revenue of 1.42 trillion KRW for fiscal year 2024, up 3.4% from fiscal year 2023, and net income of 24.73 billion KRW. That is a net profit margin of 1.7% for fiscal year 2024. In Q2 2025 (the quarter ended June 30, 2025) revenue was 405.45 billion KRW, up 12.5% from a year before. Its largest business segment, Pharmaceutical Manufacturing and Sales, brought in 97% of segment revenue in fiscal year 2025; South Korea was the largest region with 83%. In Q2 2025 it reported net income of 37.76 billion KRW, against net income of 1.14 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 1.28 trillion KRW in fiscal year 2022 to 1.42 trillion KRW in fiscal year 2024, 5.4% a year on average. Daewoong Pharmaceutical reports about 1,893 full-time employees.

What stands out

  • Net income fell 79.7% in fiscal year 2024, from 121.74 billion KRW in fiscal year 2023.
  • Revenue in fiscal year 2024 was the highest of the last 4 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2024.

About Daewoong Pharmaceutical Co., Ltd

Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.

Largest shareholders

  • Daewoong Co., Ltd.52.29%
  • National Pension Service of Korea9.95%
  • Daewoong Endowment Foundation8.62%
  • Daewoong Pharmaceutical Co., Ltd0.69%
  • Hyun-ryung Park0.2557 %0.26%

Share of the company, as of September 25, 2026

Leadership

  • Chang-Jae Lee — CEO & Executive Director, 48
  • Seongsoo Park — CEO & Executive Director, 49
  • Eunkyeong Park — Executive Director

How much revenue does Daewoong Pharmaceutical make?

Daewoong Pharmaceutical reported 1.42 trillion KRW in revenue for fiscal year 2024, up 3.4% from 1.38 trillion KRW in fiscal year 2023. In Q2 2025 revenue was 405.45 billion KRW.

What is Daewoong Pharmaceutical's largest business segment?

Pharmaceutical Manufacturing and Sales, with 1.60 trillion KRW or 97% of segment revenue in fiscal year 2025. Next: Service Provision (2%) and Other (under 1%).

Where does Daewoong Pharmaceutical make most of its revenue?

South Korea: 83% of revenue by region in fiscal year 2025, followed by Export (17%).

What companies are similar to Daewoong Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Celltrion Pharm, Inc. (068760.KQ), OliX Pharmaceuticals, Inc (226950.KQ), GC Biopharma Corp. (006280.KS), HK inno.N Corporation (195940.KQ).

Has Daewoong Pharmaceutical made a profit in recent years?

Net income by fiscal year: FY2021, 24.51 billion KRW; FY2022, 42.24 billion KRW; FY2023, 121.74 billion KRW; FY2024, 24.73 billion KRW. It was profitable in each of these years.

How has Daewoong Pharmaceutical's revenue changed over the last 4 fiscal years?

Revenue by fiscal year: FY2021, 1.15 trillion KRW; FY2022, 1.28 trillion KRW; FY2023, 1.38 trillion KRW; FY2024, 1.42 trillion KRW.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees1,893
HeadquartersSeoul, South Korea
ExchangeKSE
TimezoneAsia/Seoul (KST)

Contact & Links

Address
12, Bongeunsa-ro 114-gil, Seoul, 135-715
Phone
82 2 550 8209
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Daewoong Pharmaceutical Co., Ltd (069620.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/069620.KS

LinkedInLinkedInXXYouTubeYouTube